Table 4 Survival analyses associated with immune check point receptor expression in patients with TNBC after NAC
Expressions in TILs | N | 5-year Disease Free Survival (DFS) (%) | p | 5-year Disease Specific Survival (DSS) (%) | p |
|---|---|---|---|---|---|
PDL-1 ≥ 1% (+) vs < 1% (−) | 29/28 | 62.5% vs 39.5% | 0.141 | 67.2% vs 50.4% | 0.132 |
PDL-1 ≥ 5% (+) vs < 5% (−) | 25/32 | 65.3% vs 38.9% | 0.096 | 66.2% vs 53.3% | 0.213 |
PDL-1 High (≥10%) vs Low (< 10%)a | 26/31 | 66.2% vs 37.5% | 0.062 | 67.6% vs 51.5% | 0.145 |
PDL-1 ≥ 10% (+) vs < 10% (−) | 18/39 | 67.4% vs 42.9% | 0.087 | 69.9% vs 54.0% | 0.197 |
PDL-1 ≥ 20% (+) vs < 20% (−) | 15/42 | 50.0% vs 51.3% | 0.996 | 51.9% vs 62.1% | 0.651 |
PD-1 ≥ 1% (+) vs < 1% (−) | 38/23 | 50.6% vs 61.6% | 0.121 | 51.4% vs 62.7% | 0.082 |
PD-1 ≥ 5% (+) vs < 5% (−) | 26/35 | 54.2% vs 56.1% | 0.593 | 58.1% vs 69.1% | 0.270 |
PD-1 High(≥10%) vs Low(< 10%)a | 24/37 | 56.8% vs 54.8% | 0.517 | 59.6% vs 66.9% | 0.263 |
PD-1 ≥ 10% (+) vs < 10% (−) | 10/51 | 67.5% vs 49.4% | 0.193 | 72.9% vs 57.4% | 0.439 |
PD-1 ≥ 20% (+) vs < 20% (−) | 6/55 | 83.3% vs 52.2% | 0.277 | 83.3% vs 59.5% | 0.570 |
LAG-3 ≥ 1% (+) vs < 1% (−) | 16/45 | 68.8% vs 50.8% | 0.370 | 60.6% vs 59.4% | 0.778 |
LAG-3 ≥ 5% (+) vs < 5% (−) | 7/54 | 57.1% vs 55.3% | 0.804 | 71.4% vs 62.9% | 0.339 |
LAG-3 High(≥10%) vs Low(< 10%)a | 6/55 | 66.7% vs 53.9% | 0.815 | 66.7% vs 61.3% | 0.683 |
TIM3 ≥ 1% (+) vs < 1% (−) | 42/19 | 50.5% vs 65.6% | 0.473 | 53.6% vs 72.3% | 0.524 |
TIM3 ≥ 5% (+) vs < 5% (−) | 15/46 | 52.8% vs 55.4% | 0.947 | 62.7% vs 59.2% | 0.959 |
TIM3 High (≥10%) vs Low (< 10%)a | 14/47 | 57.1% vs 55.2% | 0.314 | 68.8% vs 60.5% | 0.535 |
CTLA-4 ≥ 1% (+) vs < 1% (−) | 50/11 | 57.2% vs 45.5% | 0.272 | 63.2% vs 45.5% | 0.209 |
CTLA-4 ≥ 5% (+) vs < 5% (−) | 48/13 | 55.9% vs 53.8% | 0.595 | 61.8% vs 53.8% | 0.481 |
CTLA-4 High(≥15%) vs Low(< 15%)b | 43/18 | 63.7% vs 36.5% | 0.043 | 70.5% vs 43.2% | 0.017 |
CTLA-4 ≥ 10% (+) vs < 10% (−) | 29/32 | 60.1% vs 51.1% | 0.429 | 67.4% vs 53.6% | 0.468 |
CTLA-4 ≥ 15% (+) vs < 15% (−) | 19/42 | 74.9% vs 46.6% | 0.103 | 74.0% vs 53.8% | 0.245 |
CTLA-4 ≥ 20% (+) vs < 20% (−) | 18/43 | 72.9% vs 48.1% | 0.165 | 72.1% vs 55.0% | 0.373 |
PD1/PDL-1 ≥ 1% (+) vs < 1% (−) | 22/38 | 52.5% vs 51.3% | 0.908 | 58.4% vs 60.4% | 0.997 |
PD1/LAG3 ≥ 1% (+) vs < 1% (−) | 14/47 | 64.3% vs 52.4% | 0.619 | 64.0% vs 61.1% | 0.903 |
PD1/TIM3 ≥ 1% (+) vs < 1% (−) | 31/30 | 48.5% vs 62.2% | 0.273 | 49.4% vs 75.2% | 0.204 |
PD1/CTLA4 ≥ 1% (+) vs < 1% (−) | 33/28 | 58.6% vs 50.2% | 0.966 | 59.9% vs 65.0% | 0.984 |